Acute Lung Injury Treatment Global Market Report 2023: R&D of Novel Therapies Enhancing Acute Lung Injury Treatment Growth
March 16, 2023 08:18 ET
|
Research and Markets
Dublin, March 16, 2023 (GLOBE NEWSWIRE) -- The "Global Acute Lung Injury Treatment Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive...
BioAegis Therapeutics Announces FDA Clearance of IND for its ‘Inflammation Regulator Protein,’ Gelsolin, for the Treatment of ARDS
January 26, 2023 14:05 ET
|
BioAegis Therapeutics
NORTH BRUNSWICK, N.J., Jan. 26, 2023 (GLOBE NEWSWIRE) -- BioAegis Therapeutics, Inc., a clinical-stage company developing therapies for inflammatory diseases through a portfolio built around plasma...
Insights on the Lung Injury Global Market to 2027 - Pipelines Drugs for Treatment of Acute Lung Injury Presents Opportunities
September 07, 2022 05:33 ET
|
Research and Markets
Dublin, Sept. 07, 2022 (GLOBE NEWSWIRE) -- The "Global Lung Injury Market (2022-2027) by Therapy, Injury, End User, Geography, Competitive Analysis and the Impact of Covid-19 with Ansoff Analysis"...
BioAegis Therapeutics Announces Study Indicating Gelsolin Treatment Improves Survival and Reduces Lung Injury in Antibiotic Resistant Pneumonia
September 03, 2020 21:42 ET
|
BioAegis Therapeutics
MORRISTOWN, N.J., Sept. 03, 2020 (GLOBE NEWSWIRE) -- BioAegis Therapeutics Inc., a clinical stage, private company developing therapies for infectious, inflammatory and degenerative diseases through...